Overview
- Editors:
-
-
Mark W. Kroll
-
Tachycardia Business Unit, Pacesetter Inc., A St. Jude Medical Company, Sylmar, USA
-
Michael H. Lehmann
-
Wayne State University School of Medicine, Sinai Hospital, Detroit, USA
Access this book
Other ways to access
Table of contents (24 chapters)
-
Front Matter
Pages i-xxii
-
- Masood Akhtar, Mohammad R. Jazayeri, Jasbir S. Sra, Zalmen Blanck, Sanjay Deshpande, Anwer Dhala et al.
Pages 1-15
-
- William S. Staewen, Morton M. Mower
Pages 17-30
-
-
- Mark W. Kroll, Michael H. Lehmann, Patrick J. Tchou
Pages 63-88
-
- Igor Singer, Douglas Lang
Pages 89-129
-
-
- Susan M. Blanchard, Raymond E. Ideker, Randolph A. S. Cooper, J. Marcus Wharton
Pages 147-161
-
-
- Randall S. Nelson, Byron L. Gilman, J. Edward Shapland, Michael H. Lehmann
Pages 173-204
-
-
- Joel B. Ennis, Mark W. Kroll
Pages 223-239
-
-
- Stan M. Bach Jr., Paul Monroe
Pages 257-273
-
- Dennis A. Brumwell, Kai Kroll, Michael H. Lehmann
Pages 275-302
-
- Stan M. Bach Jr., Michael H. Lehmann, Mark W. Kroll
Pages 303-323
-
- Michael L. Hardage, Michael B. Sweeney
Pages 325-342
-
- Wolfram Grimm, Francis E. Marchlinski
Pages 343-363
-
- Richard B. Shepard, Andrew E. Epstein
Pages 365-388
-
About this book
HE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, or T"lCD," is arguably the most technologically challenging type of therapy that physicians utilize today. At the same time, engineers who design ICDs are being called upon by clinicians to extend even further the technological envelope in quest of building the "ideal" device. To the extent, however, that physicians who utilize ICDs are not sufficiently comfortable with or familiar with the engineering principles that guide ICD function, the full clinical potential of even an ideal device will not be realized. In comple mentary fashion, engineers require as full an appreciation as possi ble of the real world "boundary conditions" and clinical impact of various ICD features, if the latter are truly to be perfected. This book is intended to serve as an educational tool to foster mutual understanding and communication among physicians, engineers, and other professionals involved in ICD therapy, with the ultimate purpose of enhancing patient care. The highly varied backgrounds of such a diverse audience posed obvious challenges in the preparation of this volume. Given the overwhelmingly greater involvement of clinicians in the day-to day management and follow-up of ICD recipients, we gave high priority to the presentation of oftentimes complex yet relevant engi neering concepts in a manner that could be understandable to most clinicians.
Editors and Affiliations
-
Tachycardia Business Unit, Pacesetter Inc., A St. Jude Medical Company, Sylmar, USA
Mark W. Kroll
-
Wayne State University School of Medicine, Sinai Hospital, Detroit, USA
Michael H. Lehmann